Meticulous Research®—a renowned global market research firm—has published a comprehensive report titled "Viral Vaccines Market Size, Share, Forecast, & Trends Analysis". This report projects the viral vaccines market to reach $47.01 billion by 2031, registering a compound annual growth rate (CAGR) of 1.9% from 2024 to 2031.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5920?utm_source=article&utm_medium=social&utm_campaign=product&utm_content=02-10-2024

Market Dynamics
The growth of the viral vaccines market is significantly driven by several factors, including a robust pipeline of vaccine products, increasing government emphasis on immunization programs, and advancements in vaccine administration technologies. Furthermore, the rising use of inactivated vaccines for surgeries and treatments, alongside the expansion capabilities of biopharmaceutical products, are expected to enhance market development. The focus on therapeutic vaccines, growing utilization of adjuvants, and the emergence of highly stable and energy-efficient ultra-low temperature freezers represent additional growth opportunities for industry players.

Key Players
The report profiles prominent key players operating within the viral vaccines market, including:

Pfizer, Inc. (U.S.)
AstraZeneca plc (U.K.)
GlaxoSmithKline plc (U.K.)
Sanofi S.A. (Italy)
CSL Ltd. (Australia)
Mitsubishi Tanabe Pharma Corporation (Japan)
Merck & Co., Inc. (U.S.)
Moderna, Inc. (U.S.)
Johnson & Johnson Services, Inc. (U.S.)
Dynavax Technologies Corporation (U.S.)
Serum Institute of India Pvt. Ltd. (India)
Emergent BioSolutions, Inc. (U.S.)
Bharat Biotech International Limited (BBIL) (India)
Valneva SE (France)
Market Segmentation
The viral vaccines market is segmented by various criteria to provide an in-depth analysis:

Form: This includes Liquid Vaccines and Lyophilized Vaccines. The liquid vaccines segment is anticipated to hold the largest market share in 2024, attributed to their ease of administration and reduced risk of logistical challenges compared to lyophilized vaccines.

Vaccine Type: Among the various types, Subunit & Conjugate Vaccines are projected to lead the market in 2024. This growth is due to their absence of live components, precise pathogen targeting, and ability to elicit protective immune responses.

Virus Type: The Adenovirus segment is expected to dominate the market, benefiting from its efficiency in gene delivery, strong immune responses, and scalability compared to other virus types.

Route of Administration: Various administration routes, including Intramuscular (IM), Subcutaneous (SC), and Oral, are analyzed.

Approach: Preventive vaccines are anticipated to have a larger market share, fueled by an increasing focus on immunization to prevent chronic and infectious diseases.

Indication: The Infectious Diseases segment is projected to grow significantly, supported by the rising prevalence of vaccine-preventable diseases and global health initiatives.

Application: The Antisense Therapy segment is expected to dominate, driven by advancements in viral vector technologies and increasing healthcare expenditures.

Geography: Geographically, North America is predicted to account for the largest market share in 2024, due to its advanced research infrastructure, presence of key pharmaceutical companies, and increased awareness for vaccination.

Industry Collaborations and Innovations
Collaborative efforts among institutes, organizations, and companies are pivotal in increasing immunizations against various infectious diseases. For instance, a notable collaboration was announced in January 2024, involving ReiThera Srl (Italy), the Ragon Institute of Mass General, MIT, and Harvard (U.S.), and the International AIDS Vaccine Initiative, Inc. (IAVI) (U.S.). They are working together to develop a novel HIV vaccine candidate utilizing ReiThera’s GRAd vector, focusing on vector engineering, process development, and preclinical assessments to evaluate the vaccine's safety and immunogenicity.

Conclusion
In summary, the viral vaccines market is poised for steady growth over the coming years, driven by technological innovations, increasing public health initiatives, and expanding opportunities in emerging markets. The continued focus on vaccine development and the strategic collaborations among key industry players are expected to further enhance the market landscape.

As the world continues to face various health challenges, the role of viral vaccines becomes ever more critical, underscoring the importance of investment in research and development to safeguard global health.

Read Full Report :- https://www.meticulousresearch.com/product/viral-vaccines-market-5920

Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research